What Is Retatrutide?
Retatrutide (LY3437943) is classified as a triple agonist (glp-1/gip/glucagon) peptide. Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic effects unmatched by single or dual agonists.
It is extensively evaluated in laboratory and clinical settings for its potential to drive superior body recomposition, massive fat loss, metabolic health. Researchers target Retatrutide for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
GI side effects (nausea, diarrhea) common; investigational not FDA-approved as of 2026. Phase 3 TRIUMPH trials ongoing.
How Does Retatrutide Work?
Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic effects unmatched by single or dual agonists.
At the molecular level, Retatrutide operates through pathways characteristic of the Triple Agonist (GLP-1/GIP/Glucagon) class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with superior body recomposition, massive fat loss, metabolic health.
Expected Research Timeline
Weeks 2–4
Rapid appetite reduction; early weight loss 1-2 lbs/week
Months 2–3
10-15% body weight reduction at therapeutic dose
Long-Term
Up to 24.2% weight loss at 48 weeks (NEJM Phase 2 trial, 12mg dose)
What Does the Research Say?
The following are key findings from peer-reviewed studies on Retatrutide, indexed on PubMed and equivalent databases:
[1]Retatrutide Phase 2 trial: ~24% weight loss at 48 weeks
Jastreboff et al. (NEJM): Phase 2 RCT showing 24.2% body weight reduction at 12mg dose over 48 weeks the highest reported weight loss in any obesity drug trial to date.
Evidence: strong[2]Retatrutide Phase 1 safety and dose-dependent weight loss
First-in-human Phase 1 trial demonstrating dose-dependent weight loss, favorable safety profile, and significant HbA1c reductions across multiple dose levels.
Evidence: moderate[3]Retatrutide reduces liver fat (NAFLD sub-study)
Phase 2 sub-study showing retatrutide significantly reduces liver fat content, with ~90% of participants with baseline steatosis achieving resolution at 48 weeks.
Evidence: strong[4]Triple GLP-1/GIP/glucagon agonism pharmacological rationale
Review of the triple agonism mechanism: GLP-1 provides appetite suppression, GIP enhances GH-like metabolic effects, and glucagon drives energy expenditure and hepatic lipid oxidation.
Evidence: moderateSafety & Side Effects
GI side effects (nausea, diarrhea) common; investigational not FDA-approved as of 2026. Phase 3 TRIUMPH trials ongoing.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea | ~45% of users | moderate |
| Diarrhea | ~25% of users | mild |
| Vomiting | ~20% of users | moderate |
| Constipation | ~20% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
Retatrutide is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is Retatrutide Used?
Route
SubQ
Dose Range
2000–2000 mcg
Frequency
1x/wk
Cycle
12–12 wk
Timing: Any day, same day each week
Notes: Investigational. Phase 2 doses: 1-12mg weekly with dose escalation. Not commercially available.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Where to Source Retatrutide for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Retatrutide?
Retatrutide is a triple agonist (glp-1/gip/glucagon) peptide. Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic effects unmatched by single or dual agonists.
What are the primary research benefits of Retatrutide?
Published research identifies primary mechanisms targeting: Superior body recomposition, massive fat loss, metabolic health. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of Retatrutide?
In published pharmacokinetic data, Retatrutide demonstrates a half-life of approximately 120 hours.
Is Retatrutide FDA approved?
Retatrutide is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of Retatrutide?
Reported side effects in published literature include Nausea (~45% of users), Diarrhea (~25% of users), Vomiting (~20% of users), Constipation (~20% of users). Most are classified as moderate in severity.
How is Retatrutide administered?
In research settings, Retatrutide is typically administered via SubQ. Investigational. Phase 2 doses: 1-12mg weekly with dose escalation. Not commercially available.
Sources
- Retatrutide Phase 2 trial: ~24% weight loss at 48 weeks. View on PubMed
- Retatrutide Phase 1 safety and dose-dependent weight loss. View on PubMed
- Retatrutide reduces liver fat (NAFLD sub-study). View on PubMed
- Triple GLP-1/GIP/glucagon agonism pharmacological rationale. View on PubMed